Short Interest in CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Decreases By 97.9%

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) saw a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 150,000 shares, a decrease of 97.9% from the December 15th total of 7,300,000 shares. Based on an average daily trading volume, of 906,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 16.5% of the company’s shares are short sold.

Insider Activity

In related news, major shareholder Bioventures Opportunities G. Yk sold 8,505 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $11.00, for a total value of $93,555.00. Following the sale, the insider now owns 205,333 shares of the company’s stock, valued at $2,258,663. The trade was a 3.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold 64,300 shares of company stock valued at $529,409 over the last quarter. 18.00% of the stock is owned by company insiders.

CERo Therapeutics Stock Down 7.9 %

CERO traded down $0.22 during midday trading on Wednesday, hitting $2.58. 333,613 shares of the company were exchanged, compared to its average volume of 1,553,872. The firm’s 50 day moving average price is $11.62 and its 200-day moving average price is $12.81. CERo Therapeutics has a 1-year low of $2.51 and a 1-year high of $1,280.00.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.